MediPharm Labs has completed its medical cannabis extract to German-based Vayamed.
The company says the export is a key milestone in its goal of leveraging its pharmaceutical GMP licenses to increase consistent international medical sales. The extract has been shipped to Vayamed from the Company’s GMP facility located in Victoria, Australia.
Warren Everitt, CEO Asia Pacific, MediPharm Labs, commented: “As a pharmaceutical company specialising in precision-based cannabinoids MediPharm Labs continues to execute on delivering to its international partners.
“Making the deliveries to a leading company like Vayamed shows not only the demand for our quality products but the ability to navigate the complex regulations of international medical cannabis trade.
“It further demonstrates the value provided by our Australian business, which is already becoming a key asset for the Company as it continues to ship GMP product to a growing international market.”
“MediPharm Labs convinced us with a high level of product competence and a company philosophy that fits perfectly to our portfolio strategy and with the brand vision of Vayamed: Medicine from Nature – customised for patients,” added Thimo Schmitt-Lord, director of market development and sector innovation at Vayamed.
MediPharm said that it will be completing additional deliveries to Vayamed under the strategic partnership agreement, assisting them in providing more access to medical cannabis for German medical patients.